BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 20 Sep 2018 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned End Date changed from 26 Sep 2018 to 13 Sep 2018.
- 04 Sep 2018 Planned primary completion date changed from 26 Sep 2018 to 13 Sep 2018.